Last reviewed · How we verify

Maltodextrin (Placebo)

Jeff Taekman, M.D. · FDA-approved active Small molecule

Maltodextrin is an inert carbohydrate polymer that serves as a placebo control with no active pharmacological mechanism.

Maltodextrin is an inert carbohydrate polymer that serves as a placebo control with no active pharmacological mechanism. Used for Used as placebo control in clinical trials (not a therapeutic indication).

At a glance

Generic nameMaltodextrin (Placebo)
Also known asGlobe Plus 10 DE Maltodextrin, Univar, Canada, Intervention group, Placebo
SponsorJeff Taekman, M.D.
ModalitySmall molecule
PhaseFDA-approved

Mechanism of action

Maltodextrin is a polysaccharide derived from starch that is physiologically inert and provides no therapeutic effect. It is commonly used as a placebo comparator in clinical trials to establish baseline efficacy and safety profiles of investigational drugs. The substance is absorbed and metabolized as a simple carbohydrate without targeting any specific molecular pathway.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: